Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers

- Significant Clinical Responses and Reduction of 2HG Biomarker in Early Cohorts -
- Data Presented at AACR Corroborate Company’s Precision Medicine Approach in Targeting Cancer Metabolism; Company to Host Investor Webcast on April 6 -

Agios Pharmaceuticals, Inc. (AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, announced that data from its lead, first-in-class program AG-221 will be presented today at a Clinical Trials Symposium titled “Novel Immune and Targeted Therapies for Hematological Malignancies and Solid Tumors” at the American Association for Cancer Research (AACR) Annual Meeting 2014. These preliminary data demonstrate the clinical activity, tolerability and unique mechanism of action of AG-221 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-2 (IDH2) mutation.

Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Enter Into Definitive Merger Agreement Under Which Mallinckrodt Will Acquire Questcor For Approximately $5.6 Billion, Creating A Diversified, High-Growth Specialty Pharmaceuticals Company

--Questcor Shareholders Receive $30.00 in Cash and 0.897 Mallinckrodt Shares for Each Share of Questcor Common Stock They Own--
--Combined Company Expected to Have Significantly Increased Scale, Revenues, Profitability and Cash Flow to Deliver Sustainable Growth Built on a More Diversified Product Platform of Novel Therapeutics--
--Transaction Expected to Be Immediately Accretive to Mallinckrodt's Fiscal Year 2014 Adjusted Diluted Earnings Per Share; Expected to Be Significantly Accretive to Adjusted Diluted Earnings Per Share in Fiscal Year 2015--

Rexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014 American Association for Clinical Research Annual Meeting

• RX-3117 is effective in gemcitabine resistant human cancer cell lines

• RX-21101, a nano-polymer targeted form of docetaxel, demonstrates increased efficacy and reduced toxicity

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that it will have two poster presentations at the 2014 American Association for Cancer Research (AACR) Annual Meeting. The conference will take place in San Diego, California, on April 5-9, 2014 at the San Diego Convention Center.